ArticlePloS one2026
Early inflammation-driven damage and delayed viral clearance are associated with prolonged biliary perturbation in a Cameroonian cohort of COVID-19 patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although COVID-19-associated liver abnormalities are documented, the link between delayed viral clearance, IgG seroconversion, and inflammation remains poorly defined, particularly in Sub-Saharan African populations, where baseline liver enzymes differ from Western standards. In 38 SARS-CoV-2-positive individuals monitored at D0, D14, and D30, we quantified liver biomarkers (ALT, AST, BILT, BILD) by spectrophotometry (COBAS), plasma IL-6 by Luminex, viral load (N and ORF1ab genes) by RT-qPCR, and IgG/IgM serology. Analyses were performed in GraphPad Prism v9.0. ALT and AST rose transiently at D14, returning to baseline by D30. IL-6 peaked at D14 and correlated positively with BILT (r = 0.64, p = 0.001) and BILD (r = 0.54, p = 0.006). ORF1ab Ct at D14 correlated negatively with ALT at D0 (r = -0.67, p = 0.004) and D14 (r = -0.71, p = 0.006); N gene Ct at D14 correlated with ALT at D0 (r = -0.61, p = 0.011). Mixed-effects models identified IL-6 as the sole independent predictor of AST (β = 3.04, p = 0.005) and Ct N gene as an independent predictor of direct bilirubin (β = -0.003, p = 0.025), supporting a dual-pathway model of COVID-19-associated cholestasis. Paradoxically, IgG seropositivity independently predicted higher direct bilirubin (β = 0.06, p = 0.030) but did not mark biliary normalisation. Elevated ALT and BILT at D0 were associated with detectable viral RNA beyond D14 (P = 0.03). Participants aged >30 years drove rising BILD, with significant increases at D14 (P = 0.03) and D30 (P = 0.04) versus D0. COVID-19 liver injury follows a biphasic course: D14 alterations are inflammation-driven (IL-6), while D30 abnormalities track with delayed viral RNA clearance independent of IgG seroconversion. Extended hepatic monitoring is warranted, especially in older patients with delayed viral clearance in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.